Dear FHC, 1 & 2 are always a possibility but 3, I don't think so, in fact I think it the least likely, why ?
Well first I am sure that the board and major share holders can see the big picture and the potential, secondly the chairman along with other large share holders have control of the registry the chairman in his own right holds 34% which would in itself prevent any hostile takeover (Blocking Stake). Now that may change when we have another cap raising but he would have to get down to less than 25% for his holding not to be considered as a blocking stake and i somehow doubt that is going to happen, but who knows.
My view has always been that the CPP technology (
Cell
Penetrating
Peptides) is the master key to the companies success. All they had to do was to prove that it works the way they had always envisaged it would, and that is exactly what is happening with the current trials. I personally think we are coming down the risk curve at a rate of knots and when the CPP technology is fully proven .... give it another 12 months.... then the true value will be seen in the market cap plus some !
Along the way we will see some sort of collaboration, as i have said before i think we could do the blinding eye disease on our own . What i don't think we could do is the APKD on our own it is just to big, but boy what a nice problem to have. So how much will the market cap increase in the next 12 months. Based on what is in front of use now and assuming the wheels don't fall off then I would envisage that 3 - 5B is not out of the question.
AS they say DYOR but I am happy with mine so far
(20min delay)